- ISIN
- US84833T1034
- CUSIP
- 84833T103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 2, 2017
Highlights
- Market Cap
- $160.39M
- Enterprise Value
- $108.70M
- EPS (TTM)
- $0.39
- PE Ratio
- 7.14
- Total Revenue (TTM)
- $54.77M
- Gross Profit (TTM)
- $54.51M
- EBITDA (TTM)
- $12.49M
- Year Range
- $1.80 - $3.22
- ROA (TTM)
- 38.02%
- ROE (TTM)
- 42.39%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SPRO Performance Chart
Spero Therapeutics, Inc. (SPRO) is up 20.2% since the beginning of the year. At $3 per share, SPRO is trading 13.0% below its 52-week high of $3. Investors who bought $1,000 worth of SPRO shares 5 years ago would now be looking at an investment worth $197.
Loading charts...
Returns By Period
Spero Therapeutics, Inc. (SPRO) has returned 20.17% so far this year and 6.06% over the past 12 months.
Spero Therapeutics, Inc.
- 1D
- -1.06%
- 1M
- 12.00%
- YTD
- 20.17%
- 6M
- 22.81%
- 1Y
- 6.06%
- 3Y*
- 15.44%
- 5Y*
- -27.74%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
SPRO Monthly Returns History
Based on dividend-adjusted daily data since Nov 2, 2017, SPRO's average daily return is +0.13%, while the average monthly return is +2.60%. At this rate, an investment would double in approximately 2.3 years.
Historically, 40% of months were positive and 60% were negative. The best month was May 2025 with a return of +279.9%, while the worst month was May 2022 at -75.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.
On a daily basis, SPRO closed higher 45% of trading days. The best single day was May 28, 2025 with a return of +244.6%, while the worst single day was May 3, 2022 at -63.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.01% | -0.91% | 7.83% | 7.26% | 12.75% | -1.06% | 20.17% | ||||||
| 2025 | -16.83% | -9.46% | -7.17% | -8.61% | 279.94% | 16.00% | -20.00% | -10.78% | -9.18% | 29.26% | -1.23% | -2.92% | 126.21% |
| 2024 | 3.40% | 8.55% | 4.24% | -17.44% | 0.00% | -8.45% | 8.46% | -2.84% | -2.19% | -8.21% | -7.32% | -9.65% | -29.93% |
| 2023 | 6.94% | -20.00% | -2.03% | 22.07% | -1.69% | -16.67% | 12.41% | -7.98% | -19.33% | -10.74% | 5.56% | 28.95% | -15.03% |
| 2022 | -25.86% | -19.12% | -9.38% | -44.14% | -75.72% | -37.20% | -1.19% | 10.20% | 147.86% | -2.00% | -1.02% | -10.82% | -89.19% |
| 2021 | -6.60% | 0.33% | -18.99% | -6.52% | 5.38% | -3.72% | -4.44% | 44.30% | -4.36% | -4.62% | -18.85% | 12.35% | -17.43% |
Benchmark Metrics
Spero Therapeutics, Inc. has an annualized alpha of 23.48%, beta of 0.84, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since November 03, 2017.
- This stock participated in 149.50% of S&P 500 Index downside but only 42.99% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 23.48%
- Beta
- 0.84
- R²
- 0.02
- Upside Capture
- 42.99%
- Downside Capture
- 149.50%
Return for Risk
Risk / Return Rank
SPRO ranks 44 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Spero Therapeutics, Inc. (SPRO) and compare them to S&P 500 Index.
| SPRO | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.13 | ||
| Sortino ratioReturn per unit of downside risk | -2.54 | ||
| Omega ratioGain probability vs. loss probability | 1.07 | 1.41 | -0.34 |
| Calmar ratioReturn relative to maximum drawdown | 0.15 | 2.93 | -2.78 |
| Martin ratioReturn relative to average drawdown | 0.27 | 13.52 | -13.25 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Spero Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Spero Therapeutics, Inc. was 97.46%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Spero Therapeutics, Inc. drawdown is 87.31%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -97.46%Apr 2025 | 4y 3mo | — | 5y 5moDec 2020 - now |
COVID crash2020 | -70.48%Mar 2020 | 1y 11mo | 8mo 27d | 2y 8moApr 2018 - Dec 2020 |
2018 bear market2018 | -32.47%Feb 2018 | 3mo 3d | 1mo 23d | 4mo 26dNov 2017 - Apr 2018 |
2020 pullback2020 | -5.34%Dec 2020 | 1d | 6d | 7dDec 2020 - Dec 2020 |
2020 pullback2020 | -4.48%Dec 2020 | 0s | 3d | 3dDec 2020 - Dec 2020 |
Drawdown Indicators
| SPRO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.46% | -56.78% | -40.68% |
Max Drawdown (1Y)Largest decline over 1 year | -39.80% | -9.10% | -30.70% |
Max Drawdown (3Y)Largest decline over 3 years | -68.89% | -18.90% | -49.99% |
Max Drawdown (5Y)Largest decline over 5 years | -97.13% | -25.43% | -71.70% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -87.31% | -0.74% | -86.57% |
Average DrawdownAverage peak-to-trough decline | -62.29% | -10.72% | -51.57% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 22.79% | 1.97% | +20.82% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Spero Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Spero Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for SPRO, comparing it with other companies in the Biotechnology industry. Currently, SPRO has a P/E ratio of 7.1. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SPRO relative to other companies in the Biotechnology industry. Currently, SPRO has a P/S ratio of 2.9. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SPRO in comparison with other companies in the Biotechnology industry. Currently, SPRO has a P/B value of 3.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SPRO
Add Spero Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SPRO